Administration and Timing
Your doctor will provide you with detailed instructions about the administration of Mozobil for your stem cell mobilization. Below is a general overview of Mozobil administration and timing so you know what to expect.
Timing of Mozobil
Mozobil is administered as a subcutanteous injection (under the skin) approximately 11 hours prior to each apheresis session (stem cell collection), up to a total of 4 days.
Mozobil is approved to be used in combination with granulocyte-colony stimulating factor (G-CSF). G-CSF is administered daily for 4 days prior to the first dose of Mozobil and on each morning prior to apheresis.
Mozobil is removed from the body through the kidneys in the urine. Removal of Mozobil from the body is reduced in patients with kidney (renal) problems. Your dose of Mozobil will be tailored to your kidney function by your doctor or healthcare provider.
Mozobil (plerixafor injection) is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM).
Important Safety Information for Mozobil (plerixafor injection)
- Mozobil is not intended for hematopoietic stem cell transplantation (HSCT) mobilization and collection in patients with leukemia.
- Mozobil in combination with G-CSF increases circulating white blood cells (WBC). Your WBC counts will be monitored.
- Thrombocytopenia (a decrease in the number of platelets circulating in the blood) has been observed in patients receiving Mozobil. Your platelet counts will be monitored.
- Cancer cells may be released from the bone marrow and subsequently collected along with your stem cells during apheresis. The potential effects of infusing cancer cells during your transplant have not been well-studied.
- Your spleen may be examined if you experience pain in the left upper stomach area or left shoulder area as these may be signs of an enlarged or burst (ruptured) spleen.
- Mozobil may harm the unborn child when administered to a pregnant woman. Scientific studies have shown that Mozobil caused harm to unborn animals. The safety of Mozobil in pregnant women has not been established in clinical trials. If you are of childbearing potential you should be advised to avoid becoming pregnant while receiving treatment with Mozobil. If this drug is used during pregnancy, or if you become pregnant while taking this drug, you should be apprised of the potential hazard to the unborn child.
- The most common adverse reactions (occurring in greater than or equal to 10% of patients) during HSC mobilization and apheresis were: diarrhea (37%), nausea (34%), tiredness (fatigue) (27%), injection site reaction (34%), headache (22%), pain in your joints (arthralgia) (13%), dizziness (11%), and vomiting (10%).
Please see full Prescribing Information